Business Trends– category –
-
Stoke Space Raises $1 Billion in Series E Funding for Reusable Rocket Development, Total Funding Reaches $2.3 Billion
Stoke Space Technologies, Inc. USA Overview Stoke Space Technologies, a rocket company, completed the initial closing of its Series E funding round, securing $1 billion, bringing its total funding to $2.3 billion. This capital will be al... -
Ionis’ Zanvastro (Zilganersen) Gains FDA Approval as First Disease-Modifying ASO Therapy for Alexander Disease
Fierce Pharma USA Overview Ionis Pharmaceuticals has received FDA approval for Zanvastro (zilganersen), an antisense oligonucleotide (ASO) therapy, as the first disease-modifying treatment for Alexander disease. Zanvastro operates by spe... -
Recorna and Starna Therapeutics Partner to Advance RNA Gene Editing for Lung Diseases Leveraging STAR LNP Technology
Insight, China's Pharmaceutical Industry China Overview Chinese firms Recorna Biotechnology and Starna Therapeutics have formed a strategic partnership to develop RNA gene editing therapeutics for lung diseases. The collaboration will le... -
Ribo Life Science’s siRNA Therapeutic Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Insight, China's Pharmaceutical Industry China Overview Ribo Life Science's siRNA therapeutic, vortosiran (BD4059), has received European Medicines Agency (EMA) approval for a clinical trial aimed at stroke prevention in atrial fibrillat... -
Daiichi Sankyo/AstraZeneca’s Datroway Receives US FDA Approval for First-Line Metastatic TNBC, EMA CHMP Gives Positive Opinion
Chemistry Today USA Overview Datroway (datopotamab deruxtecan), the TROP2-directed DXd ADC co-developed by Daiichi Sankyo and AstraZeneca, has received US FDA approval as a first-line treatment for unresectable or metastatic triple-negat... -
First-in-Class Bispecific ADC BL-B01D1 Shows Antitumor Activity in Phase Ib Trial for Relapsed Extensive-Stage Small Cell Lung Cancer
ASCO Post USA Overview The first-in-class bispecific antibody-drug conjugate (ADC), izalontamab brengitecan (iza-bren, BL-B01D1), demonstrated promising antitumor activity in a Phase Ib study for relapsed extensive-stage small cell lung ... -
Argo Biopharma Presents Positive Phase II Data for siRNA Therapeutic BW-20805 in Hereditary Angioedema, Demonstrates Significant Reduction in Attack Rate
PR Newswire USA Overview Argo Biopharma announced positive updated Phase II results for its siRNA therapeutic, BW-20805, for Hereditary Angioedema (HAE) at the Bradykinin Symposium 2026. BW-20805 significantly reduced monthly HAE attack ... -
Soufflé Therapeutics Initiates Phase I/II Clinical Trial for Muscle-Targeted siRNA Conjugate SFL-0821 in FSHD
allsci.com USA Overview Soufflé Therapeutics has commenced a Phase I/II clinical trial for SFL-0821, a novel antibody-siRNA conjugate designed for patients with Facioscapulohumeral Muscular Dystrophy (FSHD). SFL-0821 specifically targets... -
Inhaled siRNA Therapy ARO-RAGE Confirms Safety, Tolerability, and Lung Target Engagement in Pulmonary Inflammation Trial
Springer Nature Communities International Overview In a Phase 1/2a clinical trial, the inhaled siRNA therapeutic ARO-RAGE, targeting the Receptor for Advanced Glycation End Products (RAGE), demonstrated a favorable safety profile, good t... -
Arrowhead’s siRNA Therapeutic Plozasiran Achieves Approximately 80% Triglyceride Reduction in Severe Hypertriglyceridemia Patients
TCTMD USA Overview Arrowhead Pharmaceuticals' siRNA therapeutic, plozasiran (Redemplo), demonstrated potent efficacy in SHASTA-3 and SHASTA-4 trials, reducing triglyceride levels by approximately 80% in patients with severe hypertriglyce...
